VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

Direxion Daily Semicondct Bear 3X ETF

United States Oil Fund

Direxion Financial Bear 3X Shar

Direxion Daily Small Cap Bear 3X ETF

Bank Of Montreal

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Technology Bear 3X Shares

VS TR -1x Short VIX Futures ETF

Direxion Daily Semicondct Bull 3X ETF

Direxion Daily Financial Bull 3X ETF

Direxion Daily Small Cap Bull 3X ETF

ProShares UltraPro Dow30

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Technology Bull 3X ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

ProShares UltraShort Bloomberg Natrl Gas

AgEagle Aerial Systems Inc. Common Stock

Oracle Corporation Common Stock

Bunge Limited Bunge Limited

Halliburton Company Common Stock

Civitas Resources Inc. Common Stock

CVR Energy Inc. Common Stock

Occidental Petroleum Corporation Common Stock

Northern Oil and Gas Inc. Common Stock

Raytheon Technologies Corporation Common Stock

Nutrien Ltd. Common Shares

Archer Aviation Inc. Class A Common Stock

Carvana Co. Class A Common Stock

ChargePoint Holdings Inc. Common Stock

Hillenbrand Inc Common Stock

Sensata Technologies Holding plc Ordinary Shares

MGM Resorts International Common Stock

JELD-WEN Holding Inc. Common Stock

Granite Point Mortgage Trust Inc. Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Carnival Corporation Common Stock

Click here to get full coverage on How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com

How the (MLYS) price action is used to our Advantage  news.stocktradersdaily.com

How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com

Click here to get full coverage on Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?  simplywall.st

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st

Click here to get full coverage on New Analyst Forecast: $MLYS Given 'Hold' Rating - Nasdaq

New Analyst Forecast: $MLYS Given 'Hold' Rating  Nasdaq

New Analyst Forecast: $MLYS Given 'Hold' Rating - Nasdaq

Click here to get full coverage on Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News - GuruFocus

Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News  GuruFocus

Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News - GuruFocus

Click here to get full coverage on Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy  Yahoo Finance

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha

Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS)  Seeking Alpha

Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha

Click here to get full coverage on MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS  TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Click here to get full coverage on Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development - Stock Titan

Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development  Stock Titan

Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development - Stock Titan

Click here to get full coverage on MLYS Skyrockets on Positive Topline Results - Wall Street Pit

MLYS Skyrockets on Positive Topline Results  Wall Street Pit

MLYS Skyrockets on Positive Topline Results - Wall Street Pit

Click here to get full coverage on Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock  GlobeNewswire

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - Yahoo Finance

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going  Yahoo Finance

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - Yahoo Finance

Click here to get full coverage on Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - Stock Titan

Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development  Stock Titan

Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - Stock Titan

Click here to get full coverage on Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?  Yahoo Finance

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Click here to get full coverage on Clinical-Stage Biotech Mineralys Therapeutics Sets Q1 Earnings Date: Key Updates on Hypertension Pipeline Expected - Stock Titan

Clinical-Stage Biotech Mineralys Therapeutics Sets Q1 Earnings Date: Key Updates on Hypertension Pipeline Expected  Stock Titan

Clinical-Stage Biotech Mineralys Therapeutics Sets Q1 Earnings Date: Key Updates on Hypertension Pipeline Expected - Stock Titan

Click here to get full coverage on Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - Stock Titan

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development  Stock Titan

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - Stock Titan

Click here to get full coverage on Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns  Yahoo Finance

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Click here to get full coverage on Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan

Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial  Stock Titan

Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan

Click here to get full coverage on Mineralys Hypertension Drug Shows Strong Results in Two Pivotal Trials - Stock Titan

Mineralys Hypertension Drug Shows Strong Results in Two Pivotal Trials  Stock Titan

Mineralys Hypertension Drug Shows Strong Results in Two Pivotal Trials - Stock Titan

Click here to get full coverage on Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan

Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results  Stock Titan

Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan

Click here to get full coverage on MLYS stock touches 52-week high at $15.41 amid market optimism - Investing.com

MLYS stock touches 52-week high at $15.41 amid market optimism  Investing.com

MLYS stock touches 52-week high at $15.41 amid market optimism - Investing.com

Click here to get full coverage on Is Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth? - simplywall.st

Is Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?  simplywall.st

Is Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth? - simplywall.st

Click here to get full coverage on Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update  GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March  Insider Monkey

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey

Click here to get full coverage on Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan

Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial  Stock Titan

Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan

Click here to get full coverage on Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript - Insider Monkey

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript  Insider Monkey

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts (NASDAQ:MLYS) - Seeking Alpha

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts (NASDAQ:MLYS)  Seeking Alpha

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts (NASDAQ:MLYS) - Seeking Alpha

Click here to get full coverage on Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - GlobeNewswire

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock  GlobeNewswire

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial - Stock Titan

Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial  Stock Titan

Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial - Stock Titan

Click here to get full coverage on Mineralys Therapeutics Inc. (MLYS) reports earnings - Quartz

Mineralys Therapeutics Inc. (MLYS) reports earnings  Quartz

Mineralys Therapeutics Inc. (MLYS) reports earnings - Quartz

Click here to get full coverage on Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis - Stock Titan

Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis  Stock Titan

Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis - Stock Titan

Click here to get full coverage on Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension  Seeking Alpha

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha

Click here to get full coverage on Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12  Nasdaq

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq

Click here to get full coverage on Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Mineralys Therapeutics Approves Key Proposals at Annual Meeting  TipRanks

Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Click here to get full coverage on Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex  GlobeNewswire

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc. (MLYS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc. (MLYS) Stockholders to Inquire about Securities Investigation  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc. (MLYS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Click here to get full coverage on Mineralys sees a double drop in blood pressure and a stock pop - BioWorld MedTech

Mineralys sees a double drop in blood pressure and a stock pop  BioWorld MedTech

Mineralys sees a double drop in blood pressure and a stock pop - BioWorld MedTech

Click here to get full coverage on Malaysia PM says will build trade relations, not wait for U.S. tariffs - Reuters

Malaysia PM says will build trade relations, not wait for U.S. tariffs  Reuters

Malaysia PM says will build trade relations, not wait for U.S. tariffs - Reuters

Click here to get full coverage on Mineralys sees stock surge on lorundrostat data - The Pharma Letter

Mineralys sees stock surge on lorundrostat data  The Pharma Letter

Mineralys sees stock surge on lorundrostat data - The Pharma Letter

Click here to get full coverage on This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday  Benzinga

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Click here to get full coverage on Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update  GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises - Investing.com

Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises  Investing.com

Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises - Investing.com

Click here to get full coverage on Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com

Mineralys to present lorundrostat trial data at ESH 2025  Investing.com

Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com

Click here to get full coverage on Mineralys Therapeutics stock rises on better-than-expected Q1 results - Investing.com

Mineralys Therapeutics stock rises on better-than-expected Q1 results  Investing.com

Mineralys Therapeutics stock rises on better-than-expected Q1 results - Investing.com

Click here to get full coverage on Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat  TipRanks

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks

Click here to get full coverage on Mineralys Therapeutics Reports Positive Phase 3 Trial Results - TipRanks

Mineralys Therapeutics Reports Positive Phase 3 Trial Results  TipRanks

Mineralys Therapeutics Reports Positive Phase 3 Trial Results - TipRanks

Click here to get full coverage on Mineralys Therapeutics to Announce First Quarter 2025 - GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2025  GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2025 - GlobeNewswire

Click here to get full coverage on Goldman Sachs maintains buy on Mineralys stock, $24 target - Investing.com

Goldman Sachs maintains buy on Mineralys stock, $24 target  Investing.com

Goldman Sachs maintains buy on Mineralys stock, $24 target - Investing.com

Click here to get full coverage on Mineralys Therapeutics prices $175M stock offering - MSN

Mineralys Therapeutics prices $175M stock offering  MSN

Mineralys Therapeutics prices $175M stock offering - MSN

Click here to get full coverage on Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView

Mineralys Therapeutics, Inc. SEC 10-Q Report  TradingView

Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on Mineralys Therapeutics' stock price explodes after lorundrostat study results - The Business Journals

Mineralys Therapeutics' stock price explodes after lorundrostat study results  The Business Journals

Mineralys Therapeutics' stock price explodes after lorundrostat study results - The Business Journals

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Investors to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Investors to Reach Out  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Investors to Reach Out - ACCESS Newswire

Click here to get full coverage on Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com Nigeria

Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com  Investing.com Nigeria

Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com Nigeria

Click here to get full coverage on Sector Update: Health Care Stocks Decline Late Afternoon - TradingView

Sector Update: Health Care Stocks Decline Late Afternoon  TradingView

Sector Update: Health Care Stocks Decline Late Afternoon - TradingView

Click here to get full coverage on Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga

Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday  Benzinga

Mineralys Therapeutics, Inc. Common Stock (MLYS)

Price Chart

Key Statistics

Technicals

About MLYS

Latest News

How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st

New Analyst Forecast: $MLYS Given 'Hold' Rating - Nasdaq

Advanced Charts

Top Gainers

Top Losers